Adaptive Biotechnologies Corporation (ADPT)
| Market Cap | 9.26B |
| Revenue (ttm) | 92.41M |
| Net Income (ttm) | -122.27M |
| Shares Out | 134.37M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $67.74 |
| Previous Close | $67.01 |
| Change ($) | 0.73 |
| Change (%) | 1.09% |
| Day's Open | 66.71 |
| Day's Range | 65.67 - 68.16 |
| Day's Volume | 293,229 |
| 52-Week Range | 16.96 - 68.16 |
Multi-year, pan-portfolio deal extends Adaptive's proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology
During GuruFocus' annual model portfolio rebalance for 2021, the new stocks added to the Most Weighted Model Portfolio were Adaptive Biotechnologies Corp. (NASDAQ:ADPT), AerCap Holdings NV (NY...
SEATTLE, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Investors need to pay close attention to Adaptive Biotechnologies (ADPT) stock based on the movements in the options market lately.
According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarte...
MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment MRD assessment with cl...
SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive imm...
Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global, disclosed this week that his firm's top sells during the third quarter were in Amazon.com Inc. (NASDAQ:AMZN), Comcas...
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
Adaptive Biotechnologies says it's proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a s...
– Findings support upcoming launch of T-Detect ™ COVID , first T- cell test for novel coronavirus – Data support mounting evidence that measuring T- cell s is necessary to fully characteriz e ...
Adaptive Biotechnologies' (ADPT) CEO Chad Robins on Q3 2020 Results - Earnings Call Transcript
Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19.
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 3.57% and 12.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 145.45% over the past year t...
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive imm...
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotech CEO says it's working to develop the best antibody treatment for Covid-19
Adaptive biotechnologies CEO Chad Robins says the company is working night and day to develop an effective antibody Covid-19 treatment. He says the company won't be first to provide antibody t...
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immu...
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive ...
Adaptive Biotechnologies: T-Cell Explorer In COVID-19 Battle Deserves A Premium
Adaptive Biotechnologies CEO on Covid-19 research efforts, Russia vaccine claims
Chad Robins, Adaptive Biotechnologies co-founder and CEO, joins "Squawk Box" to discuss the company's research efforts to develop a Covid-19 vaccine as well as Russian President Vladimir Putin...
Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q2 2020 Results - Earnings Call Transcript
Adaptive Biotechnologies’ revenue fell 5% to $21 million in the second quarter, and its net loss more than doubled to $33.
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.33% and 3.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate t...
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials
Does this unusual biotech stock have what it takes to deliver market-beating gains?
Current tests are highly inaccurate, resulting in lengthy diagnostic journey Current tests are highly inaccurate, resulting in lengthy diagnostic journey
Topping-off ceremonies, in which workers place the last piece of structural steel for new building, have become run-of-the-mill over the past decade in Seattle’s South Lake Union neighborhood.
Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...
Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock to help accelerate the company’s work.
SEATTLE, July 14, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...
Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.
SEATTLE, July 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...
Why Adaptive Biotechnologies and Smartsheet will be mega-cap stocks in the future.
Adaptive Biotechnologies (ADPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Seattle-based Adaptive Biotechnologies and Microsoft have launched an open-access database called ImmuneCODE to catalog the many ways in which our immune systems fight off a coronavirus infect...
SEATTLE, June 08, 2020 (GLOBE NEWSWIRE) -- This release was previously disseminated on May 27, 2020 at 16:03 ET. The date and time details for the conferences have been updated. The complete...
SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive im...
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
In the realm of diagnostic tests for COVID-19, there are two main approaches: PCR tests, which detect the presence of the live virus; and serology tests, which detect antibodies that indicate ...
Revenue skyrocketed in the first quarter. But so did Adaptive's spending.
Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q1 2020 Results - Earnings Call Transcript
Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter reve...
SEATTLE, May 12, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate th...
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline o... [Read more...]
| Industry Biotechnology | IPO Date Jun 27, 2019 |
| CEO Chad Robins | Employees 453 |
| Stock Exchange NASDAQ | Ticker Symbol ADPT |
Financial Performance
In 2019, ADPT's revenue was $85.07 million, an increase of 52.83% compared to the previous year's $55.66 million. Losses were -$68.61 million, 47.7% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 62.60, which is a decrease of -7.59% from the latest price.